{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:25:23Z","timestamp":1792160723711,"version":"4.4.0"},"reference-count":70,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T00:00:00Z","timestamp":1664668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The four TCGA-based molecular prognostic groups of endometrial carcinoma (EC), i.e., POLE-mutant, mismatch repair (MMR)-deficient, p53-abnormal, and \u201cno specific molecular profile\u201d (NSMP), have recently been integrated into ESGO-ESTRO-ESP guidelines. The POLE-mutant and MMR-deficient groups are associated with high mutational load, morphological heterogeneity, and inflammatory infiltration. These groups are frequent in high-grade endometrioid, undifferentiated\/dedifferentiated, and mixed histotypes. POLE-mutant ECs show good prognosis and do not require adjuvant treatment, although the management of cases at stage &gt;II is still undefined. MMR-deficient ECs show intermediate prognosis and are currently substratified based on clinicopathological variables, some of which might not have prognostic value. These groups may benefit from immunotherapy. P53-mutant ECs are typically high-grade and often morphologically ambiguous, accounting for virtually all serous ECs, most carcinosarcomas and mixed ECs, and half of clear-cell ECs. They show poor prognosis and are treated with chemoradiotherapy; a subset may benefit from HER2 inhibitors or PARP inhibitors. The NSMP group is the most frequent TCGA group; its prognosis is highly variable and affected by clinicopathological\/molecular factors, most of which are still under evaluation. In conclusion, the TCGA classification has improved diagnosis, risk stratification, and management of EC. Further studies are needed to resolve the points of uncertainty that still exist.<\/jats:p>","DOI":"10.3390\/ijms231911684","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T22:19:27Z","timestamp":1665267567000},"page":"11684","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives"],"prefix":"10.3390","volume":"23","author":[{"given":"Damiano","family":"Arciuolo","sequence":"first","affiliation":[{"name":"Pathology Unit, Department of Woman and Child\u2019s Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Pathology Institute, Catholic University of Sacred Heart, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Travaglino","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Woman and Child\u2019s Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Pathology Unit, Department of Advanced Biomedical Sciences, University of Naples \u201cFederico II\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5443-2333","authenticated-orcid":false,"given":"Antonio","family":"Raffone","sequence":"additional","affiliation":[{"name":"Division of Gynaecology and Human Reproduction Physiopathology, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliera Univeristaria di Bologna. S. Orsola Hospital, University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Raimondo","sequence":"additional","affiliation":[{"name":"Division of Gynaecology and Human Reproduction Physiopathology, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliera Univeristaria di Bologna. S. Orsola Hospital, University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6964-5152","authenticated-orcid":false,"given":"Angela","family":"Santoro","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Woman and Child\u2019s Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Russo","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Advanced Biomedical Sciences, University of Naples \u201cFederico II\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Varricchio","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Advanced Biomedical Sciences, University of Naples \u201cFederico II\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Casadio","sequence":"additional","affiliation":[{"name":"Division of Gynaecology and Human Reproduction Physiopathology, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliera Univeristaria di Bologna. S. Orsola Hospital, University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9061-6989","authenticated-orcid":false,"given":"Frediano","family":"Inzani","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Woman and Child\u2019s Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Seracchioli","sequence":"additional","affiliation":[{"name":"Division of Gynaecology and Human Reproduction Physiopathology, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliera Univeristaria di Bologna. S. Orsola Hospital, University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mollo","sequence":"additional","affiliation":[{"name":"Gynecology and Obstetrics Unit, Department of Medicine, Surgery and Dentistry \u201cSchola Medica Salernitana\u201d, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2576-220X","authenticated-orcid":false,"given":"Massimo","family":"Mascolo","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Advanced Biomedical Sciences, University of Naples \u201cFederico II\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4473-7560","authenticated-orcid":false,"given":"Gian Franco","family":"Zannoni","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Woman and Child\u2019s Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Pathology Institute, Catholic University of Sacred Heart, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"ref_2","unstructured":"WHO Classification of Tumours Editorial Board (2020). Female Genital Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/path.5034","article-title":"The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses","volume":"244","author":"McAlpine","year":"2018","journal-title":"J. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Santoro, A., Angelico, G., Travaglino, A., Inzani, F., Arciuolo, D., Valente, M., D\u2019Alessandris, N., Scaglione, G., Fiorentino, V., and Raffone, A. (2021). New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO\/ESTRO\/ESP Guidelines. Cancers, 13.","DOI":"10.3390\/cancers13112623"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00428-020-03007-z","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with endometrial carcinoma","volume":"478","author":"Concin","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_10","first-page":"323","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Britton","year":"2019","journal-title":"J. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00404-021-06028-4","article-title":"Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer","volume":"303","author":"Raffone","year":"2021","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00404-020-05531-4","article-title":"TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma","volume":"301","author":"Travaglino","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/his.12878","article-title":"Histopathological features of endometrial carcinomas associated with POLE mutations: Implications for decisions about adjuvant therapy","volume":"68","author":"Bakhsh","year":"2016","journal-title":"Histopathology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PAS.0000000000001598","article-title":"Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features","volume":"45","author":"Hills","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1097\/PGP.0000000000000518","article-title":"Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists","volume":"38","author":"Soslow","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ygyno.2020.01.008","article-title":"Histopathological characterization of ProMisE molecular groups of endometrial cancer","volume":"157","author":"Raffone","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/his.12581","article-title":"Targeted mutation analysis of endometrial clear cell carcinoma","volume":"66","author":"Hoang","year":"2014","journal-title":"Histopathology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/cncr.30745","article-title":"Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing","volume":"123","author":"Rudd","year":"2017","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"Delair","year":"2017","journal-title":"J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/PAS.0000000000001209","article-title":"Targeted molecular and immunohistochemical analyses of endometrial clear cell carcinoma show that POLE mutations and DNA mismatch repair protein deficiencies are uncommon","volume":"43","author":"Baniak","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/modpathol.2016.132","article-title":"Molecular genetic heterogeneity in undifferentiated endometrial carcinomas","volume":"29","author":"Biscuola","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/PAS.0000000000000873","article-title":"Undifferentiated and dedifferentiated endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis","volume":"41","author":"Espinosa","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PAS.0000000000000941","article-title":"Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch\/Sucrose Nonfermentable Complex Proteins","volume":"42","author":"Hoang","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_25","first-page":"144","article-title":"SWI\/SNF\u2014Deficiency defines highly aggressive undifferentiated endometrial carcinoma","volume":"7","author":"Coatham","year":"2020","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/cjp2.18","article-title":"In-depth molecular profiling of the biphasic components of uterine carcinosarcomas","volume":"1","author":"McConechy","year":"2015","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated Molecular Characterization of Uterine Carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cncr.30971","article-title":"The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas","volume":"124","author":"Rudd","year":"2018","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-019-12985-x","article-title":"Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma","volume":"10","author":"Gotoh","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/PAS.0000000000001560","article-title":"Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium: Representation in All 4 TCGA Groups","volume":"44","author":"Howitt","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s12253-019-00784-0","article-title":"TCGA Molecular Subgroups in Endometrial Undifferentiated\/Dedifferentiated Carcinoma","volume":"26","author":"Travaglino","year":"2019","journal-title":"Pathol. Oncol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/his.13976","article-title":"Clear cell endometrial carcinoma and the TCGA classification","volume":"76","author":"Travaglino","year":"2019","journal-title":"Histopathology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s12253-020-00829-9","article-title":"TCGA Classification of Endometrial Cancer: The Place of Carcinosarcoma","volume":"26","author":"Travaglino","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/PAS.0000000000001461","article-title":"Endometrial Carcinomas with a \u201cSerous\u201d Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations","volume":"44","author":"Conlon","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/PGP.0000000000000491","article-title":"High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations","volume":"38","author":"Murali","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Gilvazquez","year":"2020","journal-title":"J. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ygyno.2021.02.029","article-title":"Clinico-pathological significance of TCGA classification and SWI\/SNF proteins expression in undifferentiated\/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification","volume":"161","author":"Santoro","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ygyno.2021.07.007","article-title":"Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis","volume":"162","author":"Travaglino","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ijgo.13937","article-title":"Prognostic value of the TCGA molecular classification in uterine carcinosarcoma","volume":"158","author":"Travaglino","year":"2021","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","article-title":"POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer","volume":"21","author":"Eggink","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: Pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/ijgc-2021-002705","article-title":"Incorporating molecular profiling into endometrial cancer management requires prospective studies","volume":"31","author":"Amant","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.0.CO;2-I","article-title":"Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinoma with microsatellite instability","volume":"88","author":"Catasus","year":"2000","journal-title":"Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s12253-020-00811-5","article-title":"Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer","volume":"26","author":"Raffone","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_46","unstructured":"Singh, N., Wong, R., Tchrakian, N., Allen, S.G., Clarke, B., and Gilks, B. (2022, September 18). Interpretation and Reporting Terminology for Mismatch Repair Protein Immunohistochemistry in Endometrial Cancer. In BAGP Guidance Document: MMR Immunohistochemistry Interpretation and Terminology; Version 1.1;. Available online: https:\/\/www.thebagp.org\/wp-content\/uploads\/download-manager-files\/1593411202wpdm_BAGP%20MMR%20IHC%20Interpretation%20June%202020.pdf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/PGP.0000000000000369","article-title":"Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium","volume":"36","author":"Leo","year":"2017","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41379-020-0501-8","article-title":"Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma","volume":"33","author":"Pasanen","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ygyno.2019.03.100","article-title":"Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers","volume":"153","author":"Moroney","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1097\/PAS.0000000000001561","article-title":"DNA Mismatch Repair-deficient Endometrial Carcinosarcomas Portend Distinct Clinical, Morphologic, and Molecular Features Compared With Traditional Carcinosarcomas","volume":"44","author":"Segura","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ygyno.2019.03.097","article-title":"Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer","volume":"154","author":"Reijnen","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s11864-022-00993-x","article-title":"Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer","volume":"23","author":"Swift","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41379-022-01102-x","article-title":"p53 immunohistochemistry in endometrial cancer: Clinical and molecular correlates in the PORTEC-3 trial","volume":"35","author":"Vermij","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility","volume":"38","author":"Ronnett","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"153025","DOI":"10.1016\/j.prp.2020.153025","article-title":"Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer","volume":"216","author":"Raffone","year":"2020","journal-title":"Pathol.\u2014Res. Pract."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/his.14400","article-title":"Endometrial endometrioid carcinoma, grade 1, is more aggressive in the elderly than in the young","volume":"79","author":"Hachisuga","year":"2021","journal-title":"Histopathology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/PAS.0000000000000640","article-title":"Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors With Different Clinicopathologic and Molecular Genetic Features","volume":"40","author":"Espinosa","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PGP.0000000000000674","article-title":"Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma","volume":"40","author":"Brett","year":"2020","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Buza, N., and Hui, P. (2022). Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma. Arch. Pathol. Lab. Med., 146.","DOI":"10.5858\/arpa.2021-0547-OA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/PAS.0000000000001870","article-title":"HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology","volume":"46","author":"Jenkins","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/PGP.0000000000000783","article-title":"HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma","volume":"41","author":"Cagaanan","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41379-018-0055-1","article-title":"Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: A TransPORTEC initiative","volume":"31","author":"Auguste","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"911695","DOI":"10.3389\/fonc.2022.911695","article-title":"Mesonephric-Like Adenocarcinoma of Uterine Corpus: A Clinicopathological and Targeted Genomic Profiling Study in a Single Institution","volume":"12","author":"Ma","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00432-019-03123-7","article-title":"Mesonephric-like adenocarcinomas of the uterine corpus: Report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma","volume":"146","author":"Horn","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/PAS.0000000000000536","article-title":"Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases","volume":"40","author":"Meng","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/PGP.0000000000000775","article-title":"FIGO Grade 3 Endometrioid Adenocarcinomas With Diffusely Aberrant \u03b2-Catenin Expression: An Aggressive Subset Resembling Cutaneous Pilomatrix Carcinomas","volume":"41","author":"Weisman","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: International randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"Horeweg","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_70","first-page":"1","article-title":"Genomic landscape of endometrial carcinomas of no specific molecular profile","volume":"Epub ahead of print","author":"Nguyen","year":"2022","journal-title":"Mod. Pathol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11684\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:45:38Z","timestamp":1760143538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,2]]},"references-count":70,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms231911684"],"URL":"https:\/\/doi.org\/10.3390\/ijms231911684","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,2]]}}}